Popovici Odette, Molnar Geza B, Popovici Florin, Janţă Denisa, Pistol Adriana, Azoicăi Doina
The National Institute of Public Health (NIPH), Bucharest;PhD student Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania.
The National Institute of Public Health (NIPH), Bucharest, Romania.
J Gastrointestin Liver Dis. 2016 Mar;25(1):25-32. doi: 10.15403/jgld.2014.1121.251.hbc.
The most recent prevalence data for hepatitis B virus (HBV) infection in Romania came from an ESEN 2 study (2002), and from a Romanian population-based study performed in 2008. Most of the previous studies were regional and performed in specific groups (blood donors, pregnant women, institutionalized people, etc) and had limited representativeness at the national level, both for HBV and hepatitis C virus (HCV) infection. The scarcity of prevalence data for HBV and HCV infection coming from the routine surveillance was also considered. The aim of our study was to obtain overall and age group specific estimates of the prevalence of HBV and HCV infections markers in Romania, in order to recommend evidence-based public health interventions. The main outcome was the proportion of persons with HBV, HCV and HBV+HCV infection markers, overall and by age group and gender.
Our seroprevalence study ensured national representativeness for the targeted hospitalized population. A prospective collection of serum samples in hospital laboratories was completed between September and November 2013, using a systematic sampling. The study respected the confidentiality of personal data. We calculated the sample size using EpiInfo7 and used Z test - Two-tailed probability for statistical significance.
The overall prevalence data estimated in our study were HBc Ab 28%, HBs Ag 4.2%, HBs Ab regardless of titer 64.1%, HBs Ab in titer of at least 10 mUI/ml and negative HBc Ab 17.5%; HCV Ab 5.6%; HBc Ab and HCV Ab 2.8%, as markers of double infection.
The overall prevalence data estimated in our study for HBs Ag (4.2%) and HCV Ab (5.6%) correspond to a medium endemicity based on the WHO criteria. The estimated prevalence of HBV and HCV infection markers in the study population should represent an opportunity for a better national prevention and control strategy.
罗马尼亚乙型肝炎病毒(HBV)感染的最新流行率数据来自2002年的一项欧洲社会经济调查(ESEN 2)研究以及2008年开展的一项罗马尼亚全国性研究。此前的大多数研究是区域性的,且针对特定群体(献血者、孕妇、机构收容人员等)进行,对于HBV和丙型肝炎病毒(HCV)感染在国家层面的代表性有限。同时也考虑到常规监测中HBV和HCV感染流行率数据的匮乏。我们研究的目的是获得罗马尼亚HBV和HCV感染标志物总体及按年龄组划分的流行率估计值,以便推荐基于证据的公共卫生干预措施。主要结果是HBV、HCV以及HBV + HCV感染标志物阳性者的比例,总体情况以及按年龄组和性别划分的情况。
我们的血清学流行率研究确保了目标住院人群的全国代表性。2013年9月至11月间,在医院实验室采用系统抽样方法前瞻性收集血清样本。该研究尊重个人数据的保密性。我们使用EpiInfo7计算样本量,并采用Z检验——双侧概率来确定统计学显著性。
我们研究中估计的总体流行率数据为:乙肝核心抗体(HBc Ab)28%,乙肝表面抗原(HBs Ag)4.2%,无论滴度的乙肝表面抗体(HBs Ab)64.1%,滴度至少为10 mUI/ml且乙肝核心抗体阴性的乙肝表面抗体17.5%;丙肝抗体(HCV Ab)5.6%;作为双重感染标志物的乙肝核心抗体和丙肝抗体2.8%。
根据世界卫生组织标准,我们研究中估计的HBs Ag(4.2%)和HCV Ab(5.6%)总体流行率数据对应中等流行程度。研究人群中HBV和HCV感染标志物的估计流行率应为制定更好的国家预防和控制策略提供契机。